The effect of moderate non-hemolytic jaundice and phototherapy on newborn behavior

S H Ju1, C H Lin

  • 1Department of Pediatrics, National Cheng Kung University Hospital, Tainan, Taiwan, R.O.C.

Zhonghua Minguo Xiao Er Ke Yi Xue Hui Za Zhi [Journal]. Zhonghua Minguo Xiao Er Ke Yi Xue Hui
|January 1, 1991
PubMed

Insights

Moderate jaundice in newborns does not impact behavior, but phototherapy may cause temporary adverse effects on infant alertness and orientation. Further research is needed to understand long-term implications.

Area of Science:

  • Neonatalogy
  • Pediatric Neurology
  • Bilirubin Metabolism

Background:

  • Moderate non-hemolytic jaundice is common in newborns.
  • The impact of jaundice and its treatment on infant behavior requires further investigation.
  • Phototherapy is a standard treatment for neonatal jaundice.

Purpose of the Study:

  • To assess the effects of moderate non-hemolytic jaundice and phototherapy on newborn behavior.
  • To evaluate the short-term and long-term behavioral changes in infants receiving phototherapy.
  • To compare the behavior of jaundiced infants treated with phototherapy, untreated jaundiced infants, and healthy controls.

Main Methods:

  • A randomized controlled trial involving 29 full-term infants with serum bilirubin (SB) 12-15 mg/dl.
  • Infants were assigned to phototherapy (PT) or no PT groups; a control group with SB < 12 mg/dl was also included.
  • Neonatal Behavioral Assessment Scales (NBAS) were administered at multiple time points.

Main Results:

  • Phototherapy did not significantly alter the clinical course of jaundice in infants with SB 12-15 mg/dl.
  • Infants receiving phototherapy showed poorer performance in orientation items on the 2nd and 3rd NBAS examinations compared to non-PT and control groups.
  • No significant behavioral differences were observed among the groups at 2 weeks of age.

Conclusions:

  • Moderate non-hemolytic jaundice (SB 12-15 mg/dl) does not affect the behavior of full-term infants.
  • Phototherapy may have short-term adverse effects on infant orientation and alertness, potentially impacting caregiver interaction.
  • Long-term behavioral effects of phototherapy require additional study.

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...